Chronic hepatitis C: This and the new era of treatment

doi:10.4254/wjh.v8.i2.92

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 2

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (18813)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

1251

WORD

545

HTML

11951

Figures (1-3)

897

Tables (1-1)

507

Sum=15151

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1757

Download

1917

Sum=3674

Jan 18, 2016 (publication date) through Mar 2, 2026

Times Cited of This Article

Times Cited (67)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Hepatol. Jan 18, 2016; 8(2): 92-106
Published online Jan 18, 2016. doi: 10.4254/wjh.v8.i2.92

Chronic hepatitis C: This and the new era of treatment

Michele Malaguarnera, Emanuele Bertino, Mariano Malaguarnera, Federico Salomone, Adriana Toro, Isidoro Di Carlo, Venerando Rapisarda, Nicoletta Bertino, Giulia Malaguarnera, Laura Scuderi, Maria Irene Ruggeri, Shirin Demma, Evelise Frazzetto, Giuseppe Rigano, Maria Proiti, Annalisa Ardiri, Gaetano Bertino

Gaetano Bertino, Annalisa Ardiri, Maria Proiti, Giuseppe Rigano, Evelise Frazzetto, Shirin Demma, Laura Scuderi, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy

Maria Irene Ruggeri, Internal Medicine Unit, ARNAS Civic Hospital, 90142 Palermo, Italy

Giulia Malaguarnera, Mariano Malaguarnera, Michele Malaguarnera, Research Centre “La Grande Senesce”, University of Catania, 95100 Catania, Italy

Giulia Malaguarnera, Michele Malaguarnera, Department of Biomedical Sciences, University of Catania, 95100 Catania, Italy

Nicoletta Bertino, Emanuele Bertino, Faculty of Pharmacy, University of Catania, 95123 Catania, Italy

Venerando Rapisarda, Occupational Medicine Unit, Department of Clinical and Experimental Medicine, University of Catania, 95100 Catania, Italy

Isidoro Di Carlo, Adriana Toro, Department of Surgical Sciences, Organ Transplantation and Advanced Technologies, University of Catania, 95100 Catania, Italy

Federico Salomone, Gastroenterology Unit, Acireale Hospital, 95024 Acireale, Catania, Italy

Author contributions: All authors contributed to this paper.

Conflict-of-interest statement: No potential conflicts of interest.

Correspondence to: Gaetano Bertino, Professor, Hepatology Unit - Department of Clinical and Experimental Medicine, University of Catania, Policlinic - Via S. Sofia n. 78, 95123 Catania, Italy. gaetanobertinounict@libero.it

Telephone: +39-09-53781573 Fax: +39-09-53781572

Received: April 23, 2015
Peer-review started: April 24, 2015
First decision: August 10, 2015
Revised: November 23, 2015
Accepted: December 17, 2015
Article in press: December 18, 2015
Published online: January 18, 2016
Processing time: 266 Days and 13.1 Hours

Abstract

Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This occurred for the availability of direct-acting antiviral agents that allow to reach sustained virologic response in approximately 90% of cases. In the near future further progress will be achieved with the use of pan-genotypic drugs with high efficacy but without side effects.

Keywords: Direct-acting antiviral agents; Nucleoside inhibitors; Boceprevir; Sofosbuvir; Telaprevir; Hepatitis C; Simeprevir; Daclatasvir; Ledipasvir; Faldaprevir; Ritonavir; Ombitasvir; Dasabuvir

Core tip: This review analyzes the current therapies for chronic hepatitis C and the future challenges of the research. So it tries to give an update on the research of hepatitis C virus (HCV) infection, providing a critical view of the emerging therapies and their impact on the future management of HCV infection. Since novel treatments for HCV infection are highly efficacious but costly, priority should be given to patients with advanced hepatic fibrosis, which is a disease that cannot be deferred.